IRIS
PEA, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.335
AS - Asia 5.067
EU - Europa 3.996
SA - Sud America 772
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 3
Totale 26.277
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.192
SG - Singapore 2.456
UA - Ucraina 1.131
CN - Cina 1.085
BR - Brasile 664
DE - Germania 611
HK - Hong Kong 602
IT - Italia 594
SE - Svezia 493
RU - Federazione Russa 344
TR - Turchia 293
VN - Vietnam 291
IE - Irlanda 217
FI - Finlandia 201
GB - Regno Unito 149
IN - India 93
CA - Canada 78
FR - Francia 51
KR - Corea 42
BE - Belgio 39
MX - Messico 38
BD - Bangladesh 34
AR - Argentina 33
ID - Indonesia 27
EC - Ecuador 25
JP - Giappone 25
ES - Italia 24
NL - Olanda 24
CZ - Repubblica Ceca 21
EU - Europa 21
IQ - Iraq 21
ZA - Sudafrica 21
EG - Egitto 17
PL - Polonia 16
VE - Venezuela 14
IR - Iran 13
LT - Lituania 13
CO - Colombia 12
IL - Israele 11
RO - Romania 10
CH - Svizzera 9
UZ - Uzbekistan 9
MA - Marocco 8
PE - Perù 8
PK - Pakistan 7
SA - Arabia Saudita 7
AT - Austria 6
KE - Kenya 6
AL - Albania 5
AZ - Azerbaigian 5
BG - Bulgaria 5
CL - Cile 5
PT - Portogallo 5
RS - Serbia 5
TH - Thailandia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
JM - Giamaica 4
JO - Giordania 4
KZ - Kazakistan 4
TG - Togo 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
BO - Bolivia 3
EE - Estonia 3
HN - Honduras 3
KG - Kirghizistan 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
MY - Malesia 3
PA - Panama 3
SD - Sudan 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
AU - Australia 2
BF - Burkina Faso 2
BH - Bahrain 2
CI - Costa d'Avorio 2
CM - Camerun 2
GA - Gabon 2
HU - Ungheria 2
KH - Cambogia 2
LB - Libano 2
LC - Santa Lucia 2
LV - Lettonia 2
PY - Paraguay 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
Totale 26.251
Salva come PNG Salva come JPEG
Città #
Fairfield 2.203
Woodbridge 1.561
Ashburn 1.295
Chandler 1.139
Houston 1.088
Singapore 1.040
Ann Arbor 962
Wilmington 839
Seattle 829
Cambridge 715
Jacksonville 635
Dallas 603
Hong Kong 593
Beijing 542
Dearborn 427
Boardman 349
Izmir 268
Princeton 237
Dublin 216
Udine 194
Des Moines 173
Los Angeles 142
San Diego 125
Redondo Beach 105
Buffalo 84
New York 77
Dong Ket 71
Ho Chi Minh City 70
Munich 70
Falls Church 58
Hanoi 58
Redmond 57
São Paulo 53
Hefei 51
Norwalk 43
Ogden 40
Brussels 38
Seoul 35
Nanjing 34
Grafing 33
Ottawa 27
Shanghai 26
Brooklyn 25
Montreal 24
Santa Clara 24
Helsinki 23
Moscow 23
Tokyo 23
Denver 22
Grugliasco 22
Guangzhou 21
Milan 21
Rio de Janeiro 21
Brasília 20
Kunming 20
Phoenix 19
London 18
Jinan 17
Rome 17
Brno 16
Chicago 16
Mumbai 16
Warsaw 16
Nuremberg 15
San Mateo 15
Trieste 15
Amsterdam 14
Johannesburg 14
Belo Horizonte 13
Bologna 13
Curitiba 13
Düsseldorf 13
Orem 13
The Dalles 13
Wuhan 13
Biên Hòa 12
Piemonte 12
San Francisco 12
West Jordan 12
Boston 11
Frankfurt am Main 11
Nanchang 11
Naples 11
Redwood City 11
Turku 11
Campinas 10
Fuzhou 10
Mexico City 10
Toronto 10
Atlanta 9
Augusta 9
Changsha 9
Chennai 9
Porto Alegre 9
San Jose 9
Simi Valley 9
Stockholm 9
Venezia 9
Ankara 8
Baghdad 8
Totale 18.044
Salva come PNG Salva come JPEG
Nome #
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 663
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? 651
A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program 254
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? 211
Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia 196
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 191
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant 191
Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings 187
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 185
Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. 180
Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. 180
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients 179
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 177
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 174
Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients 171
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases 163
Pharmacokinetic drug interaction between everolimus and antifungal triazoles in a liver transplant patient 163
Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy 163
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections 162
Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients 155
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 155
Ceftolozane/tazobactam: place in therapy 155
Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function 155
Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens 154
Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: A case report 153
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients 152
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 151
Linezolid underexposure in a patient co-treated with venlafaxine 151
- FLUCONAZOLE MONITORING IN LIVER TRANSPLANT RECIPIENTS 150
Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient 150
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 147
Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience 147
Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. 146
Antibiotic therapy in hematological neutropenic patients: what is the news? 146
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus. 146
Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful? 144
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 142
Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis 141
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 141
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 141
Monitoring polypharmacy in healthcare systems through a multi-setting survey: Should we put more attention on long term care facilities? 140
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 139
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions 139
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring 139
Effect of fluctuations of blood cyclosporine concentrations on renal function. 138
The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin 138
Is MIC increase of meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae correlated with the increase of resistance rates against some other antibiotics with Gram-negative activity? 138
Blood concentrations and clinical effect of cyclosporin in psoriasis 137
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis 137
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. 136
Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: Proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site 136
Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery 134
Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring 134
Antimicrobial treatment of bacterial infections in frail elderly patients: The difficult balance between efficacy, safety and tolerability 134
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp 134
Pharmacokinetics and drug metabolism of antibiotics in the elderly 133
High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures 132
Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis 132
Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis 132
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 131
TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients 131
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient 130
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 129
Plasma pharmacokinetics of antimicrobial agents in critically Ill patients 129
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations 129
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. 129
HIV-INFECTED PATIENTS AND LIVER TRANSPLANTATION: WHO, WHEN AND WHY 127
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 127
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 127
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections 127
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective 126
A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers 126
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia 126
Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia 125
Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia 125
Pharmacokinetic-pharmacodynamic aspecte of antimicrobial prophylaxis with teisoplanin in patients undergoing major vascular surgery 125
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? 123
Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose 123
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy 123
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin 123
Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report 122
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats 122
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure 121
Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections 121
Procalcitonin-guided antibiotic therapy: An expert consensus 121
Drugs and blood cells 120
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 118
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach 118
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents 118
Effect of the number of samples on bayesian and non-linear least-squares individualization: A study of cyclosporin treatment of haematological patients with multidrug resistance 118
Gentamicin once-daily in enterococcal endocarditis 118
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy 117
Daptomycin in solid organ transplantation: Consideration of dosage adjustments in renal impairment 117
Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies 116
Antimicrobial agents in elective surgery: Prophylaxis or "early therapy"? 116
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients 115
Ceftobiprole: drug evaluation and place in therapy 115
Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety 114
TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient 113
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 113
Totale 15.159
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.982 0 0 0 0 0 345 166 362 392 140 322 255
2021/20222.225 116 198 145 170 88 118 153 104 33 372 402 326
2022/20232.555 274 152 38 332 313 741 0 174 369 27 67 68
2023/2024668 126 53 20 10 114 79 20 57 71 40 28 50
2024/20253.674 111 318 216 126 137 198 189 253 433 281 470 942
2025/20264.207 573 860 823 575 1.105 271 0 0 0 0 0 0
Totale 26.967